Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$10.33 USD

10.33
4,776,516

-0.73 (-6.60%)

Updated Aug 8, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Spero (SPRO) Up Following Positive FDA Update for UTI Drug

by Zacks Equity Research

Spero (SPRO) surges on achieving common ground with the FDA on the regulatory path forward for tebipenem HBr.

Zacks Equity Research

Gilead (GILD) Announces Positive New Data on Breast Cancer Drug

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy shows efficacy across HER2-low and IHC0 status in pre-treated metastatic breast cancer patients.

Zacks Equity Research

Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down

by Zacks Equity Research

Jounce Therapeutics (JNCE) declines as its mid-stage study, SELECT, evaluating vopratelimab in lung cancer patients, fails to meet the primary endpoint.

Zacks Equity Research

Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC

by Zacks Equity Research

Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.

Zacks Equity Research

Gilead (GILD) Outpaces Industry in Six Months: What Lies Ahead?

by Zacks Equity Research

Gilead (GILD) gains on the back of its strong HIV franchise and promising oncology business, which should propel growth further.

Zacks Equity Research

Down 21.7% in 4 Weeks, Here's Why Dynavax Technologies (DVAX) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Dynavax Technologies (DVAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Bristol Myers (BMY) Announces Milvexian Phase II Study Results

by Zacks Equity Research

Bristol Myers (BMY) announces AXIOMATIC-SSP study results of milvexian, an investigational oral factor XIa inhibitor, for preventing new symptomatic ischemic stroke or new covert brain infarction.

Zacks Equity Research

Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre

by Zacks Equity Research

Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Zacks Equity Research

Bristol Myers (BMY) Up 14.6% YTD: Will the Performance Continue?

by Zacks Equity Research

Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue on label expansion of existing drugs.

Zacks Equity Research

Novartis (NVS) Plans to Spin Off Generics Business Sandoz

by Zacks Equity Research

Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

Zacks Equity Research

Is Dynavax Technologies (DVAX) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold

by Zacks Equity Research

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

Zacks Equity Research

Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up

by Zacks Equity Research

Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.

Zacks Equity Research

Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval

by Zacks Equity Research

Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Zacks Equity Research

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

by Zacks Equity Research

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Zacks Equity Research

Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt

by Zacks Equity Research

Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.

Zacks Equity Research

Gilead (GILD) Announces Positive Data on Breast Cancer Drug

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.

Zacks Equity Research

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

Zacks Equity Research

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

Zacks Equity Research

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

by Zacks Equity Research

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Zacks Equity Research

Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

Zacks Equity Research

How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 92%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 92.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Dynavax Technologies (DVAX) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Zacks Equity Research

Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.

Zacks Equity Research

bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.